Dyax Corp. Recognized as a “Top Place to Work” by The Boston Globe
Dyax Corp. (NASDAQ:DYAX) a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs, today announced that it has been named one of the Top Places to Work in Massachusetts by The Boston Globe.
“Great people build great businesses. At Dyax, our employees are the foundation of our organization and are behind our steady growth and winning culture,” said Gustav Christensen, President and Chief Executive Officer of Dyax. “We are honored to be recognized by The Boston Globe for our employees’ continued dedication in making Dyax a great place to work.”
The Boston Globe Top Places to Work 2014 magazine was published in The Boston Sunday Globe on November 16 and will also be featured on BostonGlobe.com. Dyax ranked 25th out of all Medium-sized Massachusetts employers, defined as companies with 100-249 employees.
The Boston Globe’s 2014 Top Places to Work survey, conducted by employee survey firm WorkplaceDynamics, measured about 73,500 individuals’ responses to statements regarding six key factors related to employee happiness, including company direction, execution, employee connection, work load and responsibility, management, and pay and benefits. Least important factors were pay, benefits and work-life balance, with survey subjects placing much higher importance on employee appreciation, confidence and a meaningful connection to the work.
Dyax is a fully integrated biopharmaceutical company focused on development and commercialization of novel biotherapeutics for unmet medical needs. The Company currently markets KALBITOR(R) (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older. Dyax is also developing DX-2930, a fully human monoclonal antibody, for the potential prophylactic treatment of HAE.
Both KALBITOR and DX-2930 were identified using Dyax’s proprietary phage display technology. Dyax has broadly licensed this technology and has a portfolio of product candidates being developed by its licensees, which it refers to as the Licensing and Funded Research Portfolio (LFRP). The Company is eligible to receive future milestones and/or royalties dependent upon the development and commercialization of these candidates. In 2014, Dyax’s licensee Eli Lilly and Company began marketing their FDA approved product, CYRAMZA(R) (ramucirumab), as a single-agent treatment for patients with advanced gastric cancer after prior chemotherapy, making this the first royalty-bearing therapeutic product from Dyax’s LFRP.
For additional information about Dyax, please visit www.dyax.com.
For additional information about KALBITOR, including full prescribing information, please visit www.KALBITOR.com.
This press release contains forward-looking statements. Statements that are not historical facts are based on Dyax’s current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which Dyax operates. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements because of risks, uncertainties and assumptions involved in any future projections. There are many factors that could cause actual results to differ from these forward-looking statements, including: risks and uncertainties relating to the clinical development of DX-2930; Dyax’s dependence on the expertise, effort, priorities and contractual obligations of third parties in the development of DX-2930 and in the marketing, sales and distribution of KALBITOR; competition from new and existing treatments for HAE; the uncertainty of patent and intellectual property protection relating to DX-2930, KALBITOR and the LFRP; Dyax’s dependence on licensees and collaborators for development, clinical trials, manufacturing, sales and distribution of product candidates in the LFRP; uncertainties as to whether one or more product candidates in the LFRP will achieve development and regulatory milestones and be commercialized and generate royalties; uncertainties regarding Lilly’s ability to successfully market CYRAMZA for the treatment of advanced gastric cancer; and other risk factors described or referred to in Item 1A, “Risk Factors” in Dyax’s most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligations to update or revise these statements, except as may be required by law.
Dyax, the Dyax logo and KALBITOR are registered trademarks of Dyax Corp.
CYRAMZA(R) is a registered trademark of Eli Lilly and Company.
Sorry. No data so far.